Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Tue, 11-Aug 4:01 PM ET)
Aquestive Therapeutics' Updated Anaphylm Film Shows Strong Progress in Human Factors and PK Studies
Market Chameleon (Tue, 11-Aug 7:22 AM ET)
Market Chameleon (Mon, 10-Aug 6:34 AM ET)
Globe Newswire (Mon, 10-Aug 7:00 AM ET)
Globe Newswire (Wed, 29-Jul 7:00 AM ET)
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Globe Newswire (Tue, 7-Jul 7:00 AM ET)
AQST’s FDA Roadblock Is Packaging, Not Product—Anaphylm’s Path Forward Looks Manageable
Market Chameleon (Mon, 2-Feb 5:29 AM ET)
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aquestive Therapeutics trades on the NASDAQ stock market under the symbol AQST.
As of September 10, 2026, AQST stock price declined to $4.99 with 3,239,369 million shares trading.
AQST has a beta of 0.18, meaning it tends to be less sensitive to market movements. AQST has a correlation of 0.00 to the broad based SPY ETF.
AQST has a market cap of $626.00 million. This is considered a Small Cap stock.
Last quarter Aquestive Therapeutics reported $14 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.06.
In the last 3 years, AQST traded as high as $7.55 and as low as $1.25.
The top ETF exchange traded funds that AQST belongs to (by Net Assets): VTI, XPH, VXF, VTWO, IWO.
AQST has underperformed the market in the last year with a price return of +0.2% while the SPY ETF gained +17.7%. However, in the short term, AQST had mixed performance relative to the market. It has outperformed in the last 3 months, returning +25.1% vs +3.1% return in SPY. But in the last 2 weeks, AQST shares have been beat by the market, returning -7.4% compared to an SPY return of -1.1%.
AQST support price is $4.97 and resistance is $5.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AQST shares will trade within this expected range on the day.
